Neurogene, Inc. (NGNE)
24.21
+0.28
(+1.17%)
USD |
NASDAQ |
Nov 16, 10:44
Neurogene Enterprise Value : 143.03M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 143.03M |
| November 12, 2026 | 142.40M |
| November 11, 2026 | 167.24M |
| November 10, 2026 | 170.96M |
| November 09, 2026 | 185.86M |
| November 06, 2026 | 171.58M |
| November 05, 2026 | 178.62M |
| November 04, 2026 | 218.56M |
| November 03, 2026 | 199.73M |
| November 02, 2026 | 198.48M |
| October 30, 2026 | 217.94M |
| October 29, 2026 | 244.22M |
| October 28, 2026 | 277.33M |
| October 27, 2026 | 206.35M |
| October 26, 2026 | 134.96M |
| October 23, 2026 | 135.16M |
| October 22, 2026 | 150.27M |
| October 21, 2026 | 187.52M |
| October 20, 2026 | 173.45M |
| October 19, 2026 | 147.99M |
| October 16, 2026 | 128.95M |
| October 15, 2026 | 143.44M |
| October 14, 2026 | 106.81M |
| October 13, 2026 | 93.98M |
| October 12, 2026 | 153.58M |
| Date | Value |
|---|---|
| October 09, 2026 | 194.14M |
| October 08, 2026 | 196.21M |
| October 07, 2026 | 183.17M |
| October 06, 2026 | 174.48M |
| October 05, 2026 | 195.59M |
| October 02, 2026 | 178.62M |
| October 01, 2026 | 197.24M |
| September 30, 2026 | 223.52M |
| September 29, 2026 | 232.38M |
| September 28, 2026 | 233.81M |
| September 25, 2026 | 231.11M |
| September 24, 2026 | 277.66M |
| September 23, 2026 | 272.59M |
| September 22, 2026 | 314.86M |
| September 21, 2026 | 298.55M |
| September 18, 2026 | 290.95M |
| September 17, 2026 | 296.02M |
| September 16, 2026 | 331.80M |
| September 15, 2026 | 316.28M |
| September 14, 2026 | 340.34M |
| September 11, 2026 | 344.62M |
| September 10, 2026 | 354.75M |
| September 09, 2026 | 382.61M |
| September 08, 2026 | 386.57M |
| September 04, 2026 | 394.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.335B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 160.67M |
| Savara, Inc. | 854.40M |
| Arrowhead Pharmaceuticals, Inc. | 6.959B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -29.02M |
| Total Expenses (Quarterly) | 29.02M |
| EPS Diluted (Quarterly) | -1.048 |
| Earnings Yield | -22.97% |
| Normalized Earnings Yield | -22.97 |